Search hospitals > Pennsylvania > Pittsburgh
Magee Women's Hospital of UPMC
Claim this profilePittsburgh, Pennsylvania 15213
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Ovarian Cancer
Conducts research for Ovarian Tumors
Conducts research for Fallopian Tube Cancer
403 reported clinical trials
41 medical researchers
Summary
Magee Women's Hospital of UPMC is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Breast Cancer, Cancer, Ovarian Cancer, Ovarian Tumors, Fallopian Tube Cancer and other specialties. Magee Women's Hospital of UPMC is involved with conducting 403 clinical trials across 529 conditions. There are 41 research doctors associated with this hospital, such as Adam Brufsky, MD, Melissa A. Burgess, Alexander B. Olawaiye, and Adam Olson.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 positive
HER2 negative
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Adam Brufsky, MDUniversity of Pittsburgh Cancer Institute (UPCI)1 year of reported clinical research
Expert in Breast Cancer
Studies Cancer
31 reported clinical trials
70 drugs studied
Melissa A. BurgessUniversity of Pittsburgh Cancer Institute (UPCI)4 years of reported clinical research
Expert in Sarcoma
Studies Soft Tissue Sarcoma
23 reported clinical trials
42 drugs studied
Alexander B. OlawaiyeUniversity of Pittsburgh Cancer Institute (UPCI)7 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
16 reported clinical trials
38 drugs studied
Adam OlsonUPMC-Shadyside Hospital5 years of reported clinical research
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
15 reported clinical trials
52 drugs studied
Clinical Trials running at Magee Women's Hospital of UPMC
Breast Cancer
Prostate Cancer
Pre-eclampsia
Cancer
Non-Small Cell Lung Cancer
Hypertension
Ovarian Cancer
Ovarian Tumors
Lung Cancer
High Blood Pressure
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Contrast-Enhanced Mammography
for Breast Abnormalities
One of the primary criticisms of mammography is that it leads to unneeded stress and anxiety from identification and biopsy of non-cancerous findings. Contrast-enhanced mammography (CEM) has the potential to significantly reduce biopsy rates for commonly seen benign breast lesions while preserving very high cancer detection. The investigators propose a prospective clinical study of patients with diagnostic mammograms rated as BIRADS 4A or 4B and scheduled for a biopsy, in which, prior to undergoing their scheduled biopsy, a CEM procedure is performed. The investigators will test the primary hypothesis that for soft tissue lesions (i.e. masses, asymmetries, architectural distortions) initially rated BI-RADS 4A/4B adding CEM will reduce, by at least 20%, the number of biopsy recommendations for actually benign cases and, at the same time, provide a negative predictive value (NPV) higher than 95%.
Recruiting3 awards Phase 43 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Magee Women's Hospital of UPMC?
Magee Women's Hospital of UPMC is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Breast Cancer, Cancer, Ovarian Cancer, Ovarian Tumors, Fallopian Tube Cancer and other specialties. Magee Women's Hospital of UPMC is involved with conducting 403 clinical trials across 529 conditions. There are 41 research doctors associated with this hospital, such as Adam Brufsky, MD, Melissa A. Burgess, Alexander B. Olawaiye, and Adam Olson.
Where is Magee Women's Hospital of UPMC located?
**Directions to Magee-Womens Hospital of UPMC, Pittsburgh, PA:**
- From the north, start on I-279 S and follow signs for I-579 S/Veterans Bridge.
- Continue onto US-19 Truck S/US-22 E/US-30 E/PA-8 S, and take exit 72B for Oakland Ave.
- Turn left onto Oakland Ave, then right onto Fifth Ave. The hospital will be on your left.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance at Magee Women's Hospital of UPMC:**
- For assistance, contact the Patient Financial Services Center at 1-800-371-8359 or email PatientFinancialServicesCenter@upmc.edu.
- Services include help with governmental assistance, payment plans, reviewing the Financial Assistance program, and support for urgent services for uninsured or underinsured patients.
- Assistance with health insurance applications through the Health Insurance Marketplace is available via UPMC's Certified Application Counselors.
**Insurance Inquiries:**
- Hospital operator: 412-641-1000
- Referral line: 866-696-2433
- UPMC Health Plan bill inquiries: Member Services at 1-888-876-2756 or TTY 711.
**During Your Stay:**
- For questions, please consult your case manager.
What insurance does Magee Women's Hospital of UPMC accept?
Magee Women's Hospital of UPMC accepts insurance plans from Highmark, Blue Cross Blue Shield, Aetna, Cigna, United Healthcare, and UPMC Health Plan. After June 30, 2019, most UPMC doctors and hospitals in the greater Pittsburgh and Erie areas will be out-of-network for Highmark commercial members with specific plans. Highmark or Blue Cross Blue Shield Medicare Advantage plan members will also lose full, in-network access to UPMC after this date.
What awards or recognition has Magee Women's Hospital of UPMC received?
Magee Women's Hospital of UPMC, located in Pittsburgh, Pennsylvania, is renowned for its dedication to women's health, partnering with the Magee-Womens Research Institute and Foundation. It excels in areas such as HIV prevention, ovarian cancer therapies, and women's cancers. The hospital is also celebrated for its environmental efforts, being a member of Practice Greenhealth since 2015, and for its exceptional care, evidenced by three Women's Choice Awards in obstetrics, cancer care, and inpatient experience.